Barooni Neeka, Chen Athena, Alaniz Sarah M, Minnier Jessica, Louey Samantha, Jonker Sonnet S
Center for Developmental Health, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, U.S.A.
Department of Pathology, Providence Portland Medical Center, Portland, OR, U.S.A.
Clin Sci (Lond). 2025 Sep 24;139(18):997-1013. doi: 10.1042/CS20256946.
Circulating lipid levels are typically low in fetuses, and exposure to high lipid levels at developmental stages prior to term birth is sometimes associated with pathology. Experimentally, near-term fetuses tolerate one week of high lipid concentrations; it is unknown whether this brief exposure to elevated circulating lipids is pathological at an earlier developmental age. We studied the physiological response to intravenous lipid emulsion during mid-gestation. Fetal sheep received intravenous Intralipid 20® (n = 9) or Lactated Ringer's Solution (n = 8) from 85.0 ± 0.7 to 97.0 ± 0.7 days of gestation (term = 147 days). Intralipid was administered according to manufacturer's recommendations, with an initial dose of 0.5-1 g/kg/d that increased daily to a maximum of 3 g/kg/d. Hemodynamic and arterial blood parameters were assessed throughout the study. Fetal growth, liver function, and lipid droplet accumulation were measured on the final day. Fetal hemodynamics and blood gases did not change as a result of the treatment. Compared with Controls, Intralipid fetuses had lower blood lactate concentrations (1.3 ± 0.2 vs. 1.0 ± 0.2 mmol/l, P=0.009) after eight days of treatment. Conjugated (0.4 ± 0.1 vs. 0.6±0.1 mg/dl, P<0.001) and unconjugated (0.3 ± 0.1 vs. 1.2 ± 0.5 mg/dl, P<0.001) bilirubin levels were higher in Intralipid-infused fetuses than in Controls. Fetal somatic growth was unchanged, but heart weight was lower in fetuses receiving Intralipid (6.9 ± 0.7 vs. 6.1±0.7 g, P=0.008). Compared with Controls, Oil Red O staining was elevated in the liver and heart of Intralipid-infused fetuses (liver score: 18.9 ± 17.2 vs. 371.7±44.2, P<0.0001; heart score: 1.8 ± 2.8 vs. 97.6 ± 60.1, P=0.0006). Our findings suggest that mid-gestation fetal sheep can tolerate intravenous lipid emulsion. Lipid accumulation in the liver and heart may precede pathologies associated with ectopic lipid storage, but further research is needed to understand the long-term consequences of Intralipid infusion at this developmental stage.
胎儿的循环脂质水平通常较低,在足月出生前的发育阶段暴露于高脂水平有时与病理状况相关。在实验中,接近足月的胎儿能耐受一周的高脂质浓度;尚不清楚在更早的发育年龄,这种短暂暴露于升高的循环脂质是否具有病理性。我们研究了妊娠中期胎儿对静脉注射脂质乳剂的生理反应。妊娠85.0±0.7至97.0±0.7天(足月为147天)的胎羊接受静脉注射英脱利匹特20®(n = 9)或乳酸林格氏液(n = 8)。英脱利匹特按照制造商的建议给药,初始剂量为0.5 - 1 g/kg/d,每日增加至最大3 g/kg/d。在整个研究过程中评估血流动力学和动脉血参数。在最后一天测量胎儿生长、肝功能和脂质滴积累情况。治疗后胎儿的血流动力学和血气没有变化。与对照组相比,接受英脱利匹特治疗8天后的胎儿血乳酸浓度较低(1.3±0.2 vs. 1.0±0.2 mmol/l,P = 0.009)。输注英脱利匹特的胎儿中结合胆红素(0.4±0.1 vs. 0.6±0.1 mg/dl,P<0.001)和非结合胆红素(0.3±0.1 vs. 1.2±0.5 mg/dl,P<0.001)水平高于对照组。胎儿的躯体生长没有变化,但接受英脱利匹特的胎儿心脏重量较低(6.9±0.7 vs. 6.1±0.7 g,P = 0.008)。与对照组相比,输注英脱利匹特的胎儿肝脏和心脏中的油红O染色增强(肝脏评分:18.9±17.2 vs. 371.7±44.2,P<0.0001;心脏评分:1.8±2.8 vs. 97.6±60.1,P = 0.0006)。我们的研究结果表明,妊娠中期的胎羊能够耐受静脉注射脂质乳剂。肝脏和心脏中的脂质积累可能先于与异位脂质储存相关的病理状况,但需要进一步研究以了解在此发育阶段输注英脱利匹特的长期后果。